JMP Securities Reaffirms Market Outperform Rating for Esperion Therapeutics (NASDAQ:ESPR)

JMP Securities restated their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) in a research report released on Tuesday,Benzinga reports. They currently have a $4.00 target price on the biopharmaceutical company's stock, down from their previous target price of $7.00.

Several other equities research analysts also recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 target price for the company. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Tuesday. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $6.75.

Esperion Therapeutics Trading Down 0.3 %

ESPR stock traded down $0.01 during trading on Tuesday, reaching $1.87. The stock had a trading volume of 1,708,732 shares, compared to its average volume of 4,447,893. Esperion Therapeutics has a 1-year low of $1.58 and a 1-year high of $3.94. The company has a market capitalization of $367.47 million, a P/E ratio of -2.91 and a beta of 1.01. The firm has a fifty day moving average price of $2.24 and a 200 day moving average price of $2.12.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors have recently modified their holdings of ESPR. Traphagen Investment Advisors LLC bought a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at about $27,000. Cibc World Markets Corp bought a new position in Esperion Therapeutics in the 4th quarter worth about $39,000. Versor Investments LP bought a new position in Esperion Therapeutics in the 3rd quarter worth about $44,000. SJS Investment Consulting Inc. bought a new position in Esperion Therapeutics in the 4th quarter worth about $55,000. Finally, Boomfish Wealth Group LLC grew its position in Esperion Therapeutics by 17.1% in the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 5,102 shares during the last quarter. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.